ChemicalBook > CAS DataBase List > TJ-M2010-5

TJ-M2010-5

Product Name
TJ-M2010-5
CAS No.
1357471-57-8
Chemical Name
TJ-M2010-5
Synonyms
TJ-M2010-5;TJ-M2010-5, 10 mM in DMSO;3-(4-Benzylpiperazin-1-yl)-N-(4-phenylthiazol-2-yl)propanamide;1-Piperazinepropanamide, 4-(phenylmethyl)-N-(4-phenyl-2-thiazolyl)-;ischemia,MIRI,Anoxia,factor,MyD88,injury,reoxygenation,inhibit,reperfusion,differentiation,Inhibitor,remodeling,myocardial,MyD88,TLR,TJ-M-2010-5,myeloid,TJM20105,TJ M2010 5
CBNumber
CB29739857
Molecular Formula
C23H26N4OS
Formula Weight
406.54
MOL File
1357471-57-8.mol
More
Less

TJ-M2010-5 Property

Density 
1.232±0.06 g/cm3(Predicted)
solubility 
DMSO : 100 mg/mL (245.98 mM; Need ultrasonic)
pka
9.36±0.50(Predicted)
form 
Solid
color 
Light yellow to yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

TJ-M2010-5 Chemical Properties,Usage,Production

Uses

TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway[1][2]. TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI)[2].

Biological Activity

TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway[1][2]. TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI)[2]. TJ-M2010-5 (40 μM) inhibits MyD88 homodimerization in transfected HEK293 cells in a concentration-dependent manner and suppresses MyD88 signaling in LPS (100 ng/mL)-responsive RAW 264.7 cells in vitro[1].TJ-M2010-5 (5-30 μM) prevents B cell proliferation and induces B cells apoptosis after stimulation with R848 (500 ng/mL)[3]. TJ-M2010-5 treatment statistically significantly reduces AOM/DSS-induced colitis and completely prevented CAC development with less related body mass loss, results in 0% mortality of treated mice, decreases cell proliferation, and increased apoptosis in colon tissue in a 10-week CAC mouse model[1].TJ-M2010-5 statistically significantly decreases TNF-α, IL-6, G-CSF, MIP-1β, IL-11, IL-17A, IL-22, and IL-23 serum concentrations in mice at both two and seven weeks postinduction, as well as TGF-β1 serum levels at seven weeks postinduction[1].

in vivo

TJ-M2010-5 treatment statistically significantly reduces AOM/DSS-induced colitis and completely prevented CAC development with less related body mass loss, results in 0% mortality of treated mice, decreases cell proliferation, and increased apoptosis in colon tissue in a 10-week CAC mouse model[1].
? TJ-M2010-5 statistically significantly decreases TNF-α, IL-6, G-CSF, MIP-1β, IL-11, IL-17A, IL-22, and IL-23 serum concentrations in mice at both two and seven weeks postinduction, as well as TGF-β1 serum levels at seven weeks postinduction[1].

Animal Model:Female BalB/c mice (6–8 weeks old) [1]
Dosage:50 mg/kg
Administration:Treated i.p. daily beginning two days before the first dextran sodium sulfate (DSS) administration throughout a 10-week observation period.
Result:Significantly prevented inflammation/CAC-related body weight loss and mortality (0% vs 53% in the control group).

References

[1]. Lin Xie, et al. Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer. J Natl Cancer Inst. 2015 Dec 28;108(4):djv364. [2]. Yan Miao,et al. Inhibition of MyD88 by a novel inhibitor reverses two-thirds of the infarct area in myocardial ischemia and reperfusion injury.Am J Transl Res. 2020 Sep 15;12(9):5151-5169.

TJ-M2010-5 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

TJ-M2010-5 Suppliers

Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266
Fax
+86-21-52996696
Country
China
ProdList
4757
Advantage
55
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Fax
021-65675885
Email
info@efebio.com
Country
China
ProdList
9803
Advantage
58
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
71826
Advantage
60
Shanghai Chaolan Chemical Technology Center
Tel
021-QQ:65489617 15618227136
Fax
21-5161 9052
Email
Sales@ATKchemical.com
Country
China
ProdList
9119
Advantage
58
MQ (shanghai) Pharmaceuticals Co., Ltd.
Tel
13761635123
Fax
1014988033@qq
Email
1014988033@qq.com
Country
China
ProdList
4941
Advantage
55
Shanghai Dongyang Biotechnology Co., Ltd.
Tel
0512-0512-13601744364 13601744364
Email
chemsharker@126.com
Country
China
ProdList
1010
Advantage
58
Guangzhou Younan Technology Co., Ltd
Tel
020-82000279 18988941452
Fax
QQ:3283937693
Email
YN_research@163.com
Country
China
ProdList
3011
Advantage
58
Chunchuang (Wuhan) Technology Co., Ltd
Tel
15727060112
Email
yutianchun2007@126.com
Country
China
ProdList
9814
Advantage
58
Jinan Jiuli Biotechnology Co. , Ltd.
Tel
15865264761
Email
486064515@qq.com
Country
China
ProdList
4798
Advantage
58
Shanghai Taopu Industrial Co., LTD
Tel
159-00573766 18018507602
Email
394643792@qq.com
Country
China
ProdList
4328
Advantage
58

1357471-57-8, TJ-M2010-5Related Search:


  • TJ-M2010-5
  • ischemia,MIRI,Anoxia,factor,MyD88,injury,reoxygenation,inhibit,reperfusion,differentiation,Inhibitor,remodeling,myocardial,MyD88,TLR,TJ-M-2010-5,myeloid,TJM20105,TJ M2010 5
  • 3-(4-Benzylpiperazin-1-yl)-N-(4-phenylthiazol-2-yl)propanamide
  • 1-Piperazinepropanamide, 4-(phenylmethyl)-N-(4-phenyl-2-thiazolyl)-
  • TJ-M2010-5, 10 mM in DMSO
  • 1357471-57-8